CN1568192A - KahalalideF制剂 - Google Patents

KahalalideF制剂 Download PDF

Info

Publication number
CN1568192A
CN1568192A CNA018182712A CN01818271A CN1568192A CN 1568192 A CN1568192 A CN 1568192A CN A018182712 A CNA018182712 A CN A018182712A CN 01818271 A CN01818271 A CN 01818271A CN 1568192 A CN1568192 A CN 1568192A
Authority
CN
China
Prior art keywords
kahalalide
infusion
cancer
reconstituted
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA018182712A
Other languages
English (en)
Chinese (zh)
Inventor
G·T·费尔克洛思
B·纽延
S·韦曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmamar SA
Original Assignee
Pharmamar SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmamar SA filed Critical Pharmamar SA
Publication of CN1568192A publication Critical patent/CN1568192A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Carbon And Carbon Compounds (AREA)
  • Liquid Crystal Substances (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
  • Superconductors And Manufacturing Methods Therefor (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CNA018182712A 2000-10-31 2001-10-31 KahalalideF制剂 Pending CN1568192A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US24447100P 2000-10-31 2000-10-31
US60/244,471 2000-10-31
US24622900P 2000-11-06 2000-11-06
US60/246,229 2000-11-06
US34844901P 2001-10-19 2001-10-19
US60/348,449 2001-10-19

Publications (1)

Publication Number Publication Date
CN1568192A true CN1568192A (zh) 2005-01-19

Family

ID=27399760

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA018182712A Pending CN1568192A (zh) 2000-10-31 2001-10-31 KahalalideF制剂

Country Status (22)

Country Link
US (1) US7473681B2 (https=)
EP (1) EP1330258B1 (https=)
JP (2) JP2004512370A (https=)
KR (1) KR100834138B1 (https=)
CN (1) CN1568192A (https=)
AT (1) ATE314084T1 (https=)
AU (2) AU1074902A (https=)
BR (1) BR0114912A (https=)
CA (1) CA2425627A1 (https=)
CY (1) CY1105009T1 (https=)
CZ (1) CZ20031211A3 (https=)
DE (1) DE60116359T2 (https=)
DK (1) DK1330258T3 (https=)
ES (1) ES2256305T3 (https=)
HK (1) HK1054192B (https=)
HU (1) HUP0600031A3 (https=)
IL (2) IL155297A0 (https=)
MX (1) MXPA03003704A (https=)
NO (1) NO331082B1 (https=)
NZ (1) NZ525243A (https=)
SK (1) SK286421B6 (https=)
WO (1) WO2002036145A2 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0002952D0 (en) * 2000-02-09 2000-03-29 Pharma Mar Sa Process for producing kahalalide F compounds
US20050054555A1 (en) * 2001-10-19 2005-03-10 Jose Jimeno Kahalalide compounds for use in cancer therapy
WO2003033012A1 (en) * 2001-10-19 2003-04-24 Pharma Mar, S.A. Kahalalide compounds for use in cancer therapy
GB0304367D0 (en) * 2003-02-26 2003-04-02 Pharma Mar Sau Methods for treating psoriasis
DK1572726T3 (da) * 2002-10-18 2011-03-28 Pharma Mar Sau 4-methylhexansyre-kahalalid F-forbindelse
NZ539093A (en) * 2002-10-18 2007-10-26 Pharma Mar Sau 4-methylhexanoic kahalaide F compound
US7507708B2 (en) 2003-02-26 2009-03-24 Pharma Mar, S.A.U. Antitumoral compounds
DE10329847A1 (de) * 2003-07-02 2005-01-20 Toximed Gmbh Pharmazeutischer Wirkstoff gegen Prostatakarzinome
GB0321066D0 (en) * 2003-09-09 2003-10-08 Pharma Mar Sau New antitumoral compounds
GB0408958D0 (en) * 2004-04-22 2004-05-26 Pharma Mar Sa Convergent synthesis for kahalalide compounds
DK1827500T3 (da) * 2004-10-26 2009-08-31 Pharma Mar Sa Pegyleret liposomal doxorubicin i kombination med ecteinescidin 743
RS50510B (sr) 2004-10-29 2010-03-02 Pharma Mar S.A., Sociedad Unipersonal Formulacije koje sadrže ekteinascidin i disaharid
GB0522082D0 (en) * 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
WO2009052379A2 (en) * 2007-10-19 2009-04-23 Pharma Mar, S.A. Improved antitumoral treatments
AU2009209541A1 (en) * 2008-01-30 2009-08-06 Pharma Mar, S.A. Improved antitumoral treatments
CN101965192A (zh) * 2008-03-07 2011-02-02 法马马有限公司 改善的抗肿瘤治疗
WO2009135939A2 (en) * 2008-05-09 2009-11-12 Pharma Mar, S.A. Depsipeptide for use in cancer therapy
HRP20231233T1 (hr) 2017-04-27 2024-01-19 Pharma Mar, S.A. Antitumorski spojevi

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5037644A (en) * 1986-10-27 1991-08-06 Cetus Corporation Pharmaceutical compositions of recombinant interleukin-2 and formulation processes
JP2799483B2 (ja) 1988-03-09 1998-09-17 大塚製薬株式会社 インターロイキン−１β組成物の安定化方法
GB8819607D0 (en) 1988-08-17 1988-09-21 Wellcome Found Novel combination
IE64738B1 (en) 1990-03-20 1995-09-06 Akzo Nv Stabilized gonadotropin containing preparations
JP2971680B2 (ja) 1991-10-02 1999-11-08 山之内製薬株式会社 組織プラスミノーゲン活性化因子含有組成物
JPH0597703A (ja) 1991-10-04 1993-04-20 Yamanouchi Pharmaceut Co Ltd 改変型組織プラスミノーゲン活性化因子含有組成物
US5550124A (en) 1991-12-10 1996-08-27 University Of Southern California Use of peripheral-type benzodiazpine sites for treatment of CNS trauma or disease
US5849704A (en) * 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
GB9302046D0 (en) * 1993-02-03 1993-03-24 Pharma Mar Sa Antiumoral compound-v
US6274551B1 (en) * 1994-02-03 2001-08-14 Pharmamar, S.A. Cytotoxic and antiviral compound
JP3927248B2 (ja) * 1995-07-11 2007-06-06 第一製薬株式会社 Ｈｇｆ凍結乾燥製剤
GB9601120D0 (en) 1996-01-19 1996-03-20 Sandoz Ltd Organic compounds
JPH1014581A (ja) 1996-07-08 1998-01-20 Morinaga Milk Ind Co Ltd ウサギ型マクロファージ・コロニー刺激因子及びこれをコードするｄｎａ断片
DE69719265T2 (de) 1996-09-06 2003-12-04 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute, Kumamoto Medizinische Zusammensetzung die Gewebeplasminogenaktivator und Nikotinamid enthält
JP4025394B2 (ja) * 1996-09-06 2007-12-19 財団法人化学及血清療法研究所 組織プラスミノーゲン活性化因子医薬組成物
GB9803448D0 (en) * 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
GB9807639D0 (en) 1998-04-14 1998-06-10 Kennedy Rheumatology Inst Anti-inflammatory agents
CN1322136A (zh) 1998-09-23 2001-11-14 马库斯·基普 用于选择性神经元辐射防护的神经亲免素类物质
GB0002952D0 (en) 2000-02-09 2000-03-29 Pharma Mar Sa Process for producing kahalalide F compounds
US20050054555A1 (en) 2001-10-19 2005-03-10 Jose Jimeno Kahalalide compounds for use in cancer therapy

Also Published As

Publication number Publication date
EP1330258B1 (en) 2005-12-28
AU2002210749B2 (en) 2006-12-21
HUP0600031A3 (en) 2012-02-28
DE60116359D1 (de) 2006-02-02
JP2004512370A (ja) 2004-04-22
CZ20031211A3 (cs) 2003-09-17
KR20030044005A (ko) 2003-06-02
IL155297A0 (en) 2003-11-23
JP2010047601A (ja) 2010-03-04
PL360848A1 (en) 2004-09-20
MXPA03003704A (es) 2004-05-04
ATE314084T1 (de) 2006-01-15
US7473681B2 (en) 2009-01-06
CY1105009T1 (el) 2010-03-03
DE60116359T2 (de) 2006-09-28
AU1074902A (en) 2002-05-15
HK1054192A1 (en) 2003-11-21
SK5022003A3 (en) 2003-12-02
BR0114912A (pt) 2003-10-14
WO2002036145A2 (en) 2002-05-10
NO331082B1 (no) 2011-10-03
HK1054192B (en) 2006-09-08
NZ525243A (en) 2005-01-28
KR100834138B1 (ko) 2008-06-02
WO2002036145A3 (en) 2002-10-17
CA2425627A1 (en) 2002-05-10
SK286421B6 (sk) 2008-09-05
DK1330258T3 (da) 2006-05-22
NO20031860D0 (no) 2003-04-25
US20040067895A1 (en) 2004-04-08
IL155297A (en) 2010-05-31
ES2256305T3 (es) 2006-07-16
HUP0600031A2 (en) 2006-05-29
EP1330258A2 (en) 2003-07-30
WO2002036145A8 (en) 2003-10-23
NO20031860L (no) 2003-06-30

Similar Documents

Publication Publication Date Title
CN1568192A (zh) KahalalideF制剂
JP5458188B2 (ja) 抗ｃｄ４０抗体の高濃度製剤
KR102430891B1 (ko) 응집체-비함유 단량체성 디프테리아 독소 융합 단백질의 제조 방법 및 치료적 용도
AU2002210749A1 (en) Kahalalide F formulation
JP2004512370A5 (https=)
CN107266551A (zh) 一种mg53突变体及其制备方法和应用
US20260022144A1 (en) Analgesic polypeptide
US11123357B2 (en) Methods and compositions for treating oral mucositis
US6476043B1 (en) Use of camptothecin derivatives, with reduced gastrointestinal toxicity
WO2020065063A1 (en) Formulations of glucagon-like-peptide-2 (glp-2) analogues
JP2019502751A5 (https=)
JP4800194B2 (ja) 乾癬の治療薬を製造するためのカハラリド化合物の使用
US20050054555A1 (en) Kahalalide compounds for use in cancer therapy
JPH04502904A (ja) 両親媒性ペプチドの投与方法およびその組成物
EP1435990A1 (en) Kahalalide compounds for use in cancer therapy
RU2292216C2 (ru) Кахалалид f
AU2002334203A1 (en) Kahalalide compounds for use in cancer therapy
CN1479622A (zh) 联合使用阿普里汀和肌肉保护剂来治疗癌症
CN102309491A (zh) 一种替加氟、吉美斯特复方注射液
CN1739543A (zh) 抗肿瘤化合物nobilisideA单乙酰化物脂质体静脉注射液及其制法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication